Non-Systemic Drugs: A Critical Review
Open Access
- 1 April 2012
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 18 (10) , 1434-1445
Abstract
Non-systemic drugs act within the intestinal lumen without reaching the systemic circulation. The first generation included polymeric resins that sequester phosphate ions, potassium ions, or bile acids for the treatment of electrolyte imbalances or hypercholesteremia. The field has evolved towards non-absorbable small molecules or peptides targeting luminal enzymes or transporters for the treatment of mineral metabolism disorders, diabetes, gastrointestinal (GI) disorders, and enteric infections. From a drug design and development perspective, non-systemic agents offer novel opportunities to address unmet medical needs while minimizing toxicity risks, but also present new challenges, including developing a better understanding and control of non-transcellular leakage pathways into the systemic circulation. The pharmacokinetic-pharmacodynamic relationship of drugs acting in the GI tract can be complex due to the variability of intestinal transit, interaction with chyme, and the complex environment of the surface epithelia. We review the main classes of nonabsorbable agents at various stages of development, and their therapeutic potential and limitations. The rapid progress in the identification of intestinal receptors and transporters, their functional characterization and role in metabolic and inflammatory disorders, will undoubtedly renew interest in the development of novel, safe, non-systemic therapeutics.Keywords
This publication has 100 references indexed in Scilit:
- The PepT1–NOD2 Signaling Pathway Aggravates Induced Colitis in MiceGastroenterology, 2011
- A Randomized Placebo-Controlled Phase IIb Trial of A3309, A Bile Acid Transporter Inhibitor, for Chronic Idiopathic ConstipationAmerican Journal of Gastroenterology, 2011
- Pharmacology, efficacy and safety of oral phosphate bindersNature Reviews Nephrology, 2011
- Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trialEuropean Heart Journal, 2011
- NPC1L1 and cholesterol transportFEBS Letters, 2010
- Postprandial lysophospholipid suppresses hepatic fatty acid oxidation: the molecular link between group 1B phospholipase A 2 and diet‐induced obesityThe FASEB Journal, 2010
- Membrane transporters in drug developmentNature Reviews Drug Discovery, 2010
- The phospholipase A2 inhibitor methyl indoxam suppresses diet‐induced obesity and glucose intolerance in miceBritish Journal of Pharmacology, 2009
- Microbial translocation is a cause of systemic immune activation in chronic HIV infectionNature Medicine, 2006
- Review on uremic toxins: Classification, concentration, and interindividual variabilityKidney International, 2003